European CHMP recommends license extension of atezolizumab (Tecentriq) for first line treatment of metastatic non-small cell lung cancer (NSCLC)

The proposed license extension is as monotherapy for first-line treatment of adults with metastatic NSCLC whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells and who do not have EGFR mutant or ALK-positive NSCLC.

Source:

European Medicines Agency